ABvac40

BIOLOGICAL2 trials

Sponsors

Araclon Biotech S.L.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseMild Cognitive Impairment

Phase 1

Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients

CompletedNCT03113812

Araclon Biotech S.L.Alzheimer's Disease

Start: 2014-01-01End: 2015-07-30Updated: 2017-04-14

Phase 2

Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD

CompletedNCT03461276

Araclon Biotech S.L.Alzheimer Disease, Mild Cognitive Impairment

Start: 2017-12-13End: 2023-03-23Updated: 2026-05-05

Related Papers

Meaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 Study

Alzheimer s & Dementia2025-12-01

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study.

2025-10-011 citations

AB1601 Phase 2 Study of ABvac40, an Anti‐Aβ40 Vaccine: Safety and Immunogenicity of a Cross‐Over Extension

Alzheimer s & Dementia2023-12-013 citations

AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer’s Disease (Vm‐AD).

Alzheimer s & Dementia2022-12-013 citations

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Alzheimer s Research & Therapy2018-01-29106 citations